Characterization of Human Non-small Cell Lung Cancer (NSCLC) Cell Lines for Expression of MHC, Co-stimulatory Molecules and Tumor-associated Antigens
Overview
Affiliations
A panel of 31 long-term non-small cell lung cancer (NSCLC) cell lines was examined for the expression of protein and/or mRNA transcripts for 11 distinct immune response related molecules or tumor associated antigens (TAA). To assess whether cytokine stimulation might up-regulate expression of the genes of interest, cells were cultured in 500 U/ml of gamma-interferon (gamma-IFN) for 48-72 h prior to analysis. Major histocompatibility complex (MHC) Class I antigens were detected by indirect immunofluorescence and were constitutively expressed on all of the cell lines. The average of the mean fluorescence intensity (MFI) measured 222+/-22. gamma-IFN stimulation produced a significant increase to 482+/-36. For MHC Class II only 7/31 cell lines (23%) exhibited constitutive expression, while gamma-IFN treatment had a dramatic effect and yielded 18/31 (58%) positive cell lines. The co-stimulatory molecules CD80 and CD86 were examined by direct immunofluorescence for cell surface expression and RT-PCR amplification for mRNA. CD80 protein was not detected at all, while an insignificant percentage of cells were positive (mean 2%) for CD86 in all cell lines tested. gamma-IFN had no apparent effect on CD80 or CD86 protein expression. Constitutive CD80 or CD86 mRNA levels were observed in 45 and 61% of the NSCLC lines, respectively. These percentages increased to 77% and 90% with gamma-IFN. Cell surface phenotypic analysis for TAA revealed positive populations in 28/31 cell lines (90%) for Her-2/neu, 18/31 (58%) for CEA and 8/31 (26%) for GD-2, with gamma-IFN having no effect. After gamma-IFN stimulation, RT-PCR amplification for Mage-1, -2, -3 and WT-1 detected mRNA in 33%, 33%, 44% and 70% of the cell lines, respectively. Overall, gamma-IFN stimulation led to the up-regulation of MHC Class I molecules and class II molecules as well as CD80 and CD86 mRNA transcripts. This survey represents the first comprehensive analysis of NSCLC cell lines for a variety of molecules that could play an important role in the generation of an NSCLC anti-tumor CD8+ cytotoxic T lymphocyte (CTL) response.
Prospects of anti-GD2 immunotherapy for retinoblastoma.
Zhang X, You W, Wang Y, Dejenie R, Wang C, Huang Y Front Immunol. 2024; 15:1499700.
PMID: 39620227 PMC: 11604707. DOI: 10.3389/fimmu.2024.1499700.
Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies.
Kandav G, Chandel A Med Oncol. 2024; 41(11):275.
PMID: 39400611 DOI: 10.1007/s12032-024-02491-6.
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies.
Zhou S, Yang H Front Immunol. 2023; 14:1129465.
PMID: 37090727 PMC: 10115980. DOI: 10.3389/fimmu.2023.1129465.
Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi S, Al-Sanea M Front Bioeng Biotechnol. 2022; 10:797440.
PMID: 35814023 PMC: 9256991. DOI: 10.3389/fbioe.2022.797440.
Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
Kandra P, Nandigama R, Eul B, Huber M, Kobold S, Seeger W Front Immunol. 2022; 13:903562.
PMID: 35720364 PMC: 9201083. DOI: 10.3389/fimmu.2022.903562.